GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.67 USD | +0.56% |
|
+0.94% | -16.50% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 27.6B 2,297B | Sales 2025 * | 27.98B 2,329B | Capitalization | 83.83B 6,978B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M 33.55B | Net income 2025 * | 6.35B 529B | EV / Sales 2024 * | 3.7 x |
| Net Debt 2024 * | 18.15B 1,511B | Net Debt 2025 * | 12.68B 1,056B | EV / Sales 2025 * | 3.45 x |
| P/E ratio 2024 * |
193
x | P/E ratio 2025 * |
13
x | Employees | 18,000 |
| Yield 2024 * |
4.6% | Yield 2025 * |
4.82% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | +0.52% | ||
| 1 week | +0.94% | ||
| Current month | +3.74% | ||
| 1 month | +1.03% | ||
| 3 months | -7.06% | ||
| 6 months | -10.65% | ||
| Current year | -16.50% |
1 week
66.84
68.04
1 month
64.3368.37
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 01/19/01 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 01/16/01 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 12/21/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 17/20/17 |
| Director/Board Member | 71 | 01/18/01 | |
Ted Love
BRD | Director/Board Member | 65 | 01/02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +11.92% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/24/22 | 67.62 | +0.49% | 1 763 616 |
| 21/24/21 | 67.29 | -0.90% | 5,701,228 |
| 20/24/20 | 67.9 | +0.27% | 4,719,854 |
| 17/24/17 | 67.72 | -0.21% | 3,579,110 |
| 16/24/16 | 67.86 | +1.27% | 4,831,970 |
Delayed Quote Nasdaq, May 22, 2024 at 11:37 pm IST
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.29
USD
Average target price
82.93
USD
Spread / Average Target
+23.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.50% | 83.83B | |
| +36.83% | 723B | |
| +32.22% | 598B | |
| -2.06% | 364B | |
| +20.29% | 331B | |
| +3.72% | 288B | |
| +16.60% | 244B | |
| +9.77% | 210B | |
| -5.15% | 208B | |
| +8.54% | 169B |
- Stock Market
- Equities
- GILD Stock
